healthcare

healthcare Articles

MacroGenics announced additional details of the results from the Phase 3 Sophia study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with...
Iovance Biotherapeutics is one of the early big winners from ASCO. The firm announced updates from ongoing clinical trials including new interim data from studies of patients with advanced cervical...
Solid Biosciences shares were crumbling on Tuesday after the firm announced its first-quarter results and an update to its midstage Duchenne muscular dystrophy trial.
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference...
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks increased.
The April 30 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
With evolving societal and regulatory landscapes, the upside potential of cannabis as a new investment strategy has emerged. Investors can use a number of ETFs to invest in the future of cannabis.
Mylan released mixed first-quarter financial results before the markets opened on Tuesday, and share plunged afterward.
With healthy living trends gaining ever more traction within the United States, they provide ample investment opportunity. ETFs help mitigate the risk of investing in individual fitness companies or...
Osmotica Pharma shares jumped on Tuesday after the firm announced results from its late-stage trial for the treatment of ptosis (droopy eyelid).
Mylan is scheduled to release its first-quarter financial results before the markets open on Tuesday, and earnings are expected to be lower than a year ago.
Cytokinetics shares took a step back on Monday after the firm announced that its midstage trial for ALS failed to meet expectations.
Nabriva Therapeutics shares dropped sharply on Wednesday after the firm received a warning from the FDA for the New Drug Application seeking marketing approval of Contepo (fosfomycin).
CVS Health released better-than-expected first-quarter financial results before the markets opened on Wednesday.